Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1051-1063, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Derkx, F. H.
Right arrow Articles by Schalekamp, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Derkx, F. H.
Right arrow Articles by Schalekamp, M. A.

Clinical Chemistry, Vol 42, 1051-1063, Copyright © 1996 by American Association for Clinical Chemistry

Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity

FH Derkx, RJ de Bruin, JM van Gool, MJ van den Hoek, CC Beerendonk, F Rosmalen, P Haima and MA Schalekamp
Department of Internal Medicine I, University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands.

Newly developed IRMAs to measure the plasma concentrations of renin and prorenin were validated for clinical use and compared with a classical enzyme kinetic assay. The IRMAs involve two monoclonal antibodies, one that reacts equally well with renin and prorenin and one that recognizes renin well but prorenin only minimally. Prorenin reactivity with the second antibody was enhanced by adding the renin inhibitor, Remikiren, to plasma. The complex of prorenin with this active-site ligand undergoes a conformational change, whereby prorenin is converted into a form that cannot be differentiated from renin by the IRMA. The linear working range of the assay was 4.0-3000 mU/L. The concentration of prorenin was calculated by subtracting the assay result obtained without Remikiren (i.e., renin) from the result obtained with Remikiren (i.e., renin plus prorenin). No more than 2% of prorenin present in plasma was detected as renin. The interassay CVs for renin quantification were 18%, 13%, and 8% at low, medium, and high concentrations, respectively. The interassay CV for calculated prorenin was 8% at both low and high concentrations. The IRMA results were highly correlated with those of an enzyme kinetic assay in healthy subjects; in patients with such conditions as primary hyperaldosteronism, renovascular hypertension, and low-, medium-, and high-renin essential hypertension; and in women undergoing gonadotropin stimulation.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
D. J. Campbell, J. Nussberger, M. Stowasser, A.H. J. Danser, A. Morganti, E. Frandsen, and J. Menard
Activity Assays and Immunoassays for Plasma Renin and Prorenin: Information Provided and Precautions Necessary for Accurate Measurement
Clin. Chem., May 1, 2009; 55(5): 867 - 877.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. D.L. Fisher, A.H. Jan Danser, J. Nussberger, W. P. Dole, and N. K. Hollenberg
Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans
Circulation, June 24, 2008; 117(25): 3199 - 3205.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
K. S. Myint, M. Watts, D. S Appleton, D. J Lomas, N. Jamieson, K. P Taylor, S. Coghill, and M. J Brown
Primary hyperaldosteronism due to adrenal microadenoma: a curable cause of refractory hypertension
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 103 - 106.
[Abstract] [PDF]

Home page
 HypertensionHome page
J. Nussberger, J.-F. Aubert, K. Bouzourene, M. Pellegrin, D. Hayoz, and L. Mazzolai
Renin Inhibition by Aliskiren Prevents Atherosclerosis Progression: Comparison With Irbesartan, Atenolol, and Amlodipine
Hypertension, May 1, 2008; 51(5): 1306 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M. J Brown
Renin: friend or foe?
Heart, September 1, 2007; 93(9): 1026 - 1033.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
Wenxia Chai, Y. M Hoedemaekers, R. H. van Schaik, M. van Fessem, I. M Garrelds, J. J Saris, D. Dooijes, F. J ten Cate, M. M. Kofflard, and A. J. Danser
Cardiac aldosterone in subjects with hypertrophic cardiomyopathy
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 225 - 230.
[Abstract] [PDF]

Home page
 HypertensionHome page
A.H. J. Danser and J. Deinum
Renin, Prorenin and the Putative (Pro)renin Receptor
Hypertension, November 1, 2005; 46(5): 1069 - 1076.
[Full Text] [PDF]

Home page
 Br J OphthalmolHome page
H Yokota, F Mori, K Kai, T Nagaoka, N Izumi, A Takahashi, T Hikichi, A Yoshida, F Suzuki, and Y Ishida
Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay
Br J Ophthalmol, July 1, 2005; 89(7): 871 - 873.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. A. de Bruin, A. Bouhuizen, S. Diederich, F. H. Perschel, F. Boomsma, and J. Deinum
Validation of a New Automated Renin Assay
Clin. Chem., November 1, 2004; 50(11): 2111 - 2116.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Piffanelli, A. Morganti, F. Mantero, A. Cianetti, G. C. Zucchelli, G. Giovannini, and D. Pelizzola
Supraregional Interlaboratory Quality-Control Survey for an Immunoradiometric Renin Assay
Clin. Chem., December 1, 2001; 47(12): 2148 - 2150.
[Full Text] [PDF]

Home page
 HypertensionHome page
J. Deinum, J. M.G. van Gool, M. J.M. Kofflard, F. J. ten Cate, and A.H. J. Danser
Angiotensin II Type 2 Receptors and Cardiac Hypertrophy in Women With Hypertrophic Cardiomyopathy
Hypertension, December 1, 2001; 38(6): 1278 - 1281.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
N. D.L. Fisher, S. Hurwitz, X. Jeunemaitre, D. A. Price, G. H. Williams, and N. K. Hollenberg
Adrenal Response to Angiotensin II in Black Hypertension: Lack of Sexual Dimorphism
Hypertension, September 1, 2001; 38(3): 373 - 378.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. J. Saris, F. H. M. Derkx, J. M. J. Lamers, P. R. Saxena, M. A. D. H. Schalekamp, and A. H. J. Danser
Cardiomyocytes Bind and Activate Native Human Prorenin : Role of Soluble Mannose 6-Phosphate Receptors
Hypertension, February 1, 2001; 37(2): 710 - 715.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. Deinum, L. Tarnow, J. M. van Gool, R. A. de Bruin, F. H. M. Derkx, M. A. D. H. Schalekamp, and H.-H. Parving
Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy
Nephrol. Dial. Transplant., August 1, 1999; 14(8): 1904 - 1911.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Deinum, F. H.M. Derkx, and M. A.D.H. Schalekamp
Improved Immunoradiometric Assay for Plasma Renin
Clin. Chem., June 1, 1999; 45(6): 847 - 854.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. J. van Veldhuisen, S. Genth-Zotz, J. Brouwer, F. Boomsma, T. Netzer, A. J. Man in 't Veld, Y. M. Pinto, K. I. Lie, and H. J. G. M. Crijns
High- versus low-dose ACE inhibition in chronic heart failure: A double-blind, placebo-controlled study of imidapril
J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1811 - 1818.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. P. R. M. Osterop, M. J. M. Kofflard, L. A. Sandkuijl, F. J. t. Cate, R. Krams, M. A. D. H. Schalekamp, and A. H. J. Danser
AT1 Receptor A/C1166 Polymorphism Contributes to Cardiac Hypertrophy in Subjects With Hypertrophic Cardiomyopathy
Hypertension, November 1, 1998; 32(5): 825 - 830.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
H. Schunkert, H.-W. Hense, A. Doring, G. A. J. Riegger, and W. Siffert
Association Between a Polymorphism in the G Protein ß3 Subunit Gene and Lower Renin and Elevated Diastolic Blood Pressure Levels
Hypertension, September 1, 1998; 32(3): 510 - 513.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S R Holmer, H-W Hense, A H J Danser, B Mayer, G A J Riegger, and H Schunkert
beta Adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics
Heart, July 1, 1998; 80(1): 45 - 48.
[Abstract] [Full Text]

Home page
 HypertensionHome page
C. A. M. van Kesteren, A. H. J. Danser, F. H. M. Derkx, D. H. W. Dekkers, J. M. J. Lamers, P. R. Saxena, and M. A. D. H. Schalekamp
Mannose 6-Phosphate Receptor–Mediated Internalization and Activation of Prorenin by Cardiac Cells
Hypertension, December 1, 1997; 30(6): 1389 - 1396.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
J. H. A. Roding, T. Weterings, and C. van der Heiden
Plasma Renin Activity: Temperature Optimum at ~45 {degrees}C
Clin. Chem., July 1, 1997; 43(7): 1243 - 1244.
[Full Text]

Home page
 CirculationHome page
A. H. J. Danser, C. A. M. van Kesteren, W. A. Bax, M. Tavenier, F. H. M. Derkx, P. R. Saxena, and M. A. D. H. Schalekamp
Prorenin, Renin, Angiotensinogen, and Angiotensin-Converting Enzyme in Normal and Failing Human Hearts : Evidence for Renin Binding
Circulation, July 1, 1997; 96(1): 220 - 226.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
F. H.M. Derkx, M. A.D.H. Schalekamp, J. E. Sealey, D. Catanzaro, and J. H. Laragh
More on Renin • The authors of the editorial referred to above reply:
Clin. Chem., April 1, 1997; 43(4): 694 - 697.
[Full Text]

Home page
 CirculationHome page
H. Schunkert, A.H. J. Danser, H.-W. Hense, F. H.M. Derkx, S. Kurzinger, and G. A.J. Riegger
Effects of Estrogen Replacement Therapy on the Renin-Angiotensin System in Postmenopausal Women
Circulation, January 7, 1997; 95(1): 39 - 45.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.